Please login to the form below
Correction: Prexige suspended in UK, Germany and Austria
PMLive news article correction: Prexige suspended in UK, Germany and Austria
We would like to correct an article which appeared in the December 2007 issue of Pharmaceutical Marketing referring to the suspension of the arthritis drug Prexige (lumiracoxib).
In this article, we referred to this being a Bayer product; this is not the case. We would like to apologise to Bayer for our mistake and have corrected the story online.
The corrected story can be found here
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Novavax gets $1.6bn from US government for coronavirus vaccine
- Communiqué Awards 2020: Results - Communiqué Awards
- Moderna clashes with US scientists over pivotal COVID-19 vaccine trials
- Mesoblast expands compassionate use COVID-19 programme
- GSK and Clover’s COVID-19 vaccine starts clinical trials
- Regeneron’s COVID-19 antibody cocktail enters phase 3 trial
- Intelligence that redefines success
- IFPMA launches AMR Action Fund to tackle antimicrobial resistance
- Merck expands partnership with Zymeworks for multispecific antibodies
- Novartis reveals full phase 3 results for Enerzair Breezhaler
- Artificial Intelligence in Digital Therapeutics
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- CHECKLIST 04: Let’s make your patient recruitment strategies a success
- From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
- Multichannel engagement and the need for greater understanding of European markets
- By Laurence Olding and Georgina James...
- A snapshot of… Exscientia
- ...
Quick links
Infographics
